{
    "cancer_info": {
        "cancer_name": "Kaposi Sarcoma"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Biopsy review by KS-expert pathologist",
            "IHC for HHV-8 (LANA-1)",
            "CD31/CD34 immunohistochemistry (if vascular origin unclear)",
            "History taking (immunosuppression, HIV status)",
            "Physical exam (skin, oral cavity, lymph nodes, edema assessment)",
            "Complete blood count (CBC) with differential",
            "Comprehensive metabolic panel",
            "HIV testing",
            "Lesion photography with measurement reference",
            "Chest X-ray (if pulmonary symptoms/advanced disease)",
            "CT/MRI abdomen/pelvis (for GI symptoms)",
            "CT chest (for abnormal X-ray)",
            "FDG-PET/CT (for suspected KICS/MCD/KSHV lymphoma)",
            "Pregnancy test (if chemotherapy/RT planned)",
            "Echocardiogram (if anthracycline use)",
            "Opportunistic infection evaluation",
            "KICS/MCD workup (CRP, KSHV viral load, IL-6/IL-10, SPEP)",
            "Fecal occult blood test (FOBT)",
            "Esophagogastroduodenoscopy (EGD)",
            "Colonoscopy",
            "Bronchoscopy",
            "T-cell subsets (CD4 count) for PWH",
            "HIV viral load testing",
            "ART adherence assessment"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "T0: Skin/lymph nodes only",
            "risk_group": "Good Risk (Requires all: T0 + I0 + S0)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Asymptomatic limited cutaneous",
                    "plan_name": "Observation",
                    "plan_details": "Monitoring without immediate intervention",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Symptomatic limited cutaneous",
                    "plan_name": "Local therapies",
                    "plan_details": "Topicals (alitretinoin, imiquimod), intralesional vinblastine (0.2 mg/mL) or bleomycin (1.5–3 U/mL), cryotherapy, RT (e.g., 20 Gy/5 fractions), marginal excision",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Relapsed/Refractory therapy",
                    "patient_subgroup": "Progression after local therapy",
                    "plan_name": "Systemic therapy",
                    "plan_details": "Initiate systemic agents if disease progression occurs",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "T1: Edema/ulceration, extensive oral/GI KS, visceral involvement",
            "risk_group": "Poor Risk (Any present: T1 or I1 or S1)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Advanced cutaneous/visceral disease",
                    "plan_name": "Liposomal doxorubicin",
                    "plan_details": "20 mg/m² IV every 2–3 weeks with cardiac monitoring",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Advanced cutaneous/visceral disease",
                    "plan_name": "Paclitaxel",
                    "plan_details": "60–135 mg/m² IV weekly or every 2–3 weeks",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Other Recommended"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Transplant-associated KS",
                    "plan_name": "Sirolimus",
                    "plan_details": "Immunosuppression switch strategy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other Recommended"
                },
                {
                    "treatment_line": "Relapsed/Refractory therapy",
                    "patient_subgroup": "First progression after durable response (>3 months)",
                    "plan_name": "Repeat prior therapy",
                    "plan_details": "Re-administer previously effective regimen if tolerated",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Relapsed/Refractory therapy",
                    "patient_subgroup": "Subsequent progressions",
                    "plan_name": "Pomalidomide",
                    "plan_details": "4–5 mg PO days 1–21/28-day cycle (REMS program required)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Relapsed/Refractory therapy",
                    "patient_subgroup": "Subsequent progressions",
                    "plan_name": "Alternative agents",
                    "plan_details": "Bortezomib, gemcitabine, lenalidomide, vinorelbine, etoposide, imatinib, albumin-bound paclitaxel",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Useful in Certain Circumstances"
                },
                {
                    "treatment_line": "Relapsed/Refractory therapy",
                    "patient_subgroup": "Classic/endemic KS",
                    "plan_name": "Immunotherapy",
                    "plan_details": "Ipilimumab + nivolumab or pembrolizumab (avoid in active KICS/MCD)",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Useful in Certain Circumstances"
                },
                {
                    "treatment_line": "Special scenario",
                    "patient_subgroup": "Corticosteroid-refractory IRIS",
                    "plan_name": "Thalidomide",
                    "plan_details": "Management of immune reconstitution inflammatory syndrome",
                    "nccn_evidence_category": "Category 3",
                    "nccn_recommendation_category": "Useful in Certain Circumstances"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "KSHV/HHV-8 (LANA-1): Required for diagnosis, indicates lifelong infection risk and relapse potential; Serum KSHV viral load: Predicts KICS/MCD development; CD4 count: Predicts KS progression/IRIS risk in PWH (prognostic even at normal levels); HIV viral load: Guides ART optimization and KS control; Inflammatory markers (IL-6, IL-10, CRP): Indicate KICS/MCD comorbidity; Cardiac function (echocardiogram): Monitors liposomal doxorubicin cardiotoxicity; ART adherence: Critical for immune reconstitution in PWH"
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：卡波西肉瘤.txt"
}